Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotech firm, will have its CEO, Kenneth A. Berlin, present at the Benzinga Biotech Small Cap Conference on March 24-25, 2021. Berlin's presentation is scheduled for 2:30 PM ET on March 24. Interested investors can view the presentation and request meetings via registration at the conference's website. Advaxis specializes in immunotherapy products utilizing bioengineered Listeria monocytogenes for enhanced anti-tumor T-cell immunity. For more details, visit advaxis.com.
Details
News Market Reaction – ADXS
The recorded move for ADXS in the trading session of this news was -3.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will participate in the Benzinga Biotech Small Cap Conference to be held March 24-25, 2021. Mr. Berlin will present on March 24th, 2021 at 2:30 pm ET.
Investors can view the presentation and request a 1x1 meeting once they register for the conference here.
Tune in to the YouTube link on Day 1 Track 1 at 2:30 pm ET for the presentation: https://www.youtube.com/watch?v=BOoOknbYO2c
About Advaxis, Inc.
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.
To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.
Investor Contact
Tim McCarthy
LifeSci Advisors, LLC
Tim@lifesciadvisors.com
(212) 915-2564
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.